Celgene (CELG) PT Set at $112.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $112.00 price target on Celgene (NASDAQ:CELG) in a report issued on Wednesday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

“The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.”,” Cantor Fitzgerald’s analyst wrote.

A number of other analysts also recently issued reports on CELG. Guggenheim reaffirmed a buy rating and issued a $147.00 price objective on shares of Celgene in a research note on Wednesday, January 10th. Credit Suisse Group set a $125.00 price objective on Celgene and gave the stock a buy rating in a research note on Monday, January 8th. SunTrust Banks set a $127.00 price objective on Celgene and gave the stock a buy rating in a research note on Monday, January 8th. Mizuho reaffirmed a buy rating and issued a $128.00 price objective on shares of Celgene in a research note on Wednesday. Finally, Deutsche Bank set a $110.00 price objective on Celgene and gave the stock a hold rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Celgene has an average rating of Buy and a consensus price target of $129.98.

Celgene (NASDAQ CELG) traded up $0.93 during midday trading on Wednesday, reaching $102.65. The company had a trading volume of 8,110,000 shares, compared to its average volume of 6,700,000. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene has a one year low of $94.55 and a one year high of $147.17. The stock has a market cap of $80,820.00, a PE ratio of 24.21, a PEG ratio of 0.66 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the firm earned $1.58 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene will post 6.71 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Counsel LLC NY grew its position in Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC grew its position in Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 11 shares during the last quarter. Savant Capital LLC grew its position in Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. grew its position in Celgene by 0.9% in the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after acquiring an additional 26 shares during the last quarter. Finally, Granite Investment Advisors LLC grew its position in Celgene by 1.1% in the 2nd quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 29 shares during the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://stocknewstimes.com/2018/01/21/celgene-celg-pt-set-at-112-00-by-cantor-fitzgerald-2.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply